|Other titles||Ovarian cancer|
|Contributions||National Cancer Institute (U.S.)., National Institutes of Health (U.S.). Office of Medical Applications of Research.|
|LC Classifications||RC280.O8 N53 1994|
|The Physical Object|
|Pagination||v, 112 p. :|
|Number of Pages||112|
Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer. May;21(4) doi: /IGC.0beb Get this from a library! NIH Consensus Development Conference on Ovarian Cancer: Screening, Treatment, and Followup: NIH Consensus Development Conference, aPRIL , , Masur Auditorium, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. [National Institutes of Health (U.S.). Office of Medical Applications of Research.;. In , the first National Institutes of Health (NIH) Consensus Conference on Ovarian Cancer released recommendations for the chemotherapeutic management of newly diagnosed or post-operative ovarian cancer (NIH Consensus Development Panel on Ovarian Cancer, ). Based on the results of chemotherapy trials that had been conducted in the. The consensus statements have been used by numerous professional organizations to develop guidelines for clinical practice; the over CDP statements can be found in the online archive. In addition, the NIH CDP has served as a model for consensus conference programs developed in .
On April 5 through 7, , the National Cancer Institute, together with the Office of Medical Applications of Research of the National Institutes of Health, convened a Consensus Development Conference on Ovarian Cancer: Screening, Treatment, and Followup. The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo, Japan, in November are reported. Three topics were reviewed and the following statements are recommended: (i) Surgery: the subgroups that should be considered in first-line ovarian. The ESMO-ESGO consensus conference on ovarian cancer was held on April in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four. The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women with ovarian cancer.
Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after and most cases occur after age The consensus statements regarding first-line therapies in women with ovarian cancer, reached at the Fifth Ovarian Cancer Consensus Conference held in Tokyo, Japan, in November are reported. Three topics were reviewed and the following statements are recommended: (i) . The National Institutes of Health held a Consensus Development Conference on ovarian cancer in April One of the issues that was addressed was the current status of screening capabilities for ovarian cancer. This paper reports the findings of the Consensus Development . 2 = Starting in , press conferences were held on the third day of the conference and an NIH press release is made available online. 3 = A printed Program and Abstract book is prepared for each conference beginning in , this document includes the agenda, panel roster, speaker roster, and speaker abstracts.